Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 23,410 shares, a drop of 73.1% from the August 31st total of 86,934 shares. Based on an average daily trading volume, of 121,189 shares, the short-interest ratio is currently 0.2 days. Approximately 0.6% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts have commented on SBFM shares. Weiss Ratings upgraded shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday. Wall Street Zen upgraded shares of Sunshine Biopharma to a “hold” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $70.00.

Sunshine Biopharma Stock Down 2.9%

SBFM stock traded down $0.02 on Monday, reaching $0.82. 35,510 shares of the company’s stock were exchanged, compared to its average volume of 723,713. The stock has a fifty day moving average of $1.20 and a 200-day moving average of $4.58. The firm has a market cap of $3.53 million, a PE ratio of -0.08 and a beta of 1.17. Sunshine Biopharma has a twelve month low of $0.78 and a twelve month high of $24.30.

Sunshine Biopharma (NASDAQ:SBFM) last released its earnings results on Thursday, August 13th. The company reported ($1.15) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.05. Sunshine Biopharma had a negative return on equity of 26.36% and a negative net margin of 17.94%.The company had revenue of $9.26 million during the quarter, compared to the consensus estimate of $8.70 million. On average, equities research analysts predict that Sunshine Biopharma will post -1.95 EPS for the current fiscal year.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc (NASDAQ:SBFM) is a pharmaceutical and biotechnology company focused on the development of therapies for cancer and other serious diseases. Its research and development activities are centered on proprietary drug candidates intended to address unmet medical needs.

The company’s lead oncology candidate is Adva-27a, a small-molecule topoisomerase II inhibitor being investigated for potential use against advanced solid tumors, including certain cancers that may be resistant to existing treatments.